Theriva Biologics, Inc. — 2014 Q2 Form 10-Q Summary
Entity note: The supplied filing is for Synthetic Biologics, Inc., not Theriva Biologics, Inc. This summary reflects the filing text provided. The reporting period ended June 30, 2014; the interim financial statements are unaudited.
Business context and reporting period
Synthetic Biologics was a clinical-stage biotechnology company developing anti-infective and gastrointestinal drug and biologic candidates, as well as oral estriol (Trimesta) for multiple sclerosis. The company reported no product revenue in the presented statements and said it did not expect near-term revenue before product commercialization.
Key financial metrics
| Metric | Q2 / six months ended June 30, 2014 | Comparable period |
|---|---|---|
| Revenue | No revenue reported in the statements | No revenue line reported |
| Operating expenses | Q2: $4.651 million; six months: $8.490 million | Q2 2013: $2.461 million; six months 2013: $4.701 million |
| Net loss | Q2: $4.556 million; six months: $8.394 million | Q2 2013: $2.497 million; six months 2013: $4.725 million |
| Loss per share | Q2: $0.08; six months: $0.14 | Q2 2013: $0.06; six months 2013: $0.11 |
| Operating cash flow | Six months: cash used of $6.765 million | Six months 2013: cash used of $3.295 million |
| Cash and cash equivalents | $7.843 million at June 30 | $14.625 million at December 31, 2013 |
| Current assets / current liabilities | $9.232 million / $1.232 million | $16.216 million / $1.027 million at December 31, 2013 |
| Debt | No debt reported on the balance sheet | Not applicable |
Gross or operating margins are not meaningful because the filing reports no revenue. Total assets were $9.289 million and stockholders’ equity was $8.057 million at June 30, 2014. Cash declined by $6.782 million in the first half, while financing activities provided only $4,000. The filing reports an accumulated deficit of $89.7 million.
Material changes versus prior comparable periods
- Six-month operating expenses rose 81% year over year, driven by research and development expense, which increased 139% to $5.554 million, and general and administrative expense, which increased 23% to $2.936 million.
- Q2 operating expenses rose 89% year over year. Management attributed the increase to expanded development, research and manufacturing activity in the C. difficile, C-IBS and Pertussis programs, as well as executive compensation and higher stock-based compensation.
- Six-month net loss widened to $8.394 million from $4.725 million. Stock-based compensation expense was $1.217 million for the first half of 2014, versus $864,000 in 2013.
- Cash fell from $14.625 million at year-end 2013 to $7.843 million at June 30, 2014. Accounts payable rose to $1.079 million from $142,000, while accrued liabilities declined to $153,000 from $885,000.
Outlook, management commentary, risks and unusual items
- Pipeline plans: Management intended to file an IND and begin Phase Ia/Ib studies of SYN-004 in Q4 2014, with preliminary Phase I data expected by year-end and a Phase II study planned for the first half of 2015. For SYN-010, it planned a Phase II study in the second half of 2014, with topline results expected in mid-2015. SYN-005 Phase I was expected to begin in the first half of 2015, followed by a planned Phase II in the second half of 2015. These are forward-looking plans, not reported outcomes.
- Trimesta: The company reported positive topline Phase II results for relapsing-remitting MS, including a 47% reduction in relapse rate at 12 months (p=0.03) and a trend toward a 32% reduction at 24 months (p=0.15). It planned to present additional results in September 2014 and was evaluating next steps and potential strategic partners. A separate Phase II cognitive dysfunction trial was enrolling.
- Funding risk: The company had no committed financing sources and expected continued operating losses and negative operating cash flow. It warned that additional capital might not be available on acceptable terms, or at all, and that equity financing could dilute shareholders. Insufficient funding could delay or curtail development.
- Other risks: Development and regulatory timelines, licensing and collaboration progress, clinical trial outcomes, and intellectual property costs could affect funding needs and plans. Meda AB had postponed planned flupirtine fibromyalgia trials following European regulatory restrictions; future milestones and royalties were uncertain.
- Equity compensation: The company granted 1,732,500 options in the first half of 2014, with stated grant-date fair value of approximately $4.1 million. Unrecognized option compensation was $4.5 million, expected to be expensed through April 2017.
- Reporting status: The cover identifies the company as a smaller reporting company, while a note says it exceeded the $75 million public-float threshold on June 30, 2014 and was no longer an SRC. The filing says auditor attestation on internal controls would be required in the 2014 Form 10-K.
- Management stated disclosure controls were effective as of June 30, 2014, with no material change in internal control reported. No legal proceedings were disclosed.
Important facts for investors to verify
- Confirm the issuer identity: the filing names Synthetic Biologics, Inc., whereas the request metadata names Theriva Biologics, Inc.
- Verify the company’s cash runway, actual subsequent financing, and any changes to the stated clinical development timelines.
- Review full clinical data and subsequent regulatory developments for Trimesta and the SYN-004, SYN-010 and SYN-005 programs.
- Reconcile the filing’s smaller-reporting-company cover designation with its disclosure that the public-float threshold had been exceeded.
- Assess potential dilution from outstanding options and warrants and the future expense associated with unrecognized stock-based compensation.